摘要:
Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.
摘要:
Compositions which comprise delivery vehicles having stably associated therewith a cytidine analog and a platinum agent are useful in achieving enhanced therapeutic effects when combinations of these drugs are administered.
摘要:
Compositions which comprise delivery vehicles having stably associated therewith non-antagonistic combinations of two or more agents, such as antineoplastic agents, are useful in achieving non-antagonistic effects when combinations of drugs are administered.
摘要:
Novel compounds inhibiting ATR protein kinase include compounds of formula (I) disclosed herein, as well as liposome formulations comprising ATR protein kinase inhibitor compounds. The compositions are useful for the treatment of cancer.
摘要:
Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.
摘要:
Provided is a composition suitable for parenteral administration to a subject, which composition comprises daunorubicin and cytarabine encapsulated in liposomes in a mole ratio of daunorubicin:cytarabine of about 1:5, wherein said liposomes have a mean diameter in the range of 4.5 nm to less than 250 nm; and wherein the pharmacokinetics of the composition are controlled by the liposomes, whereby the daunorubicin and cytarabine agents are to be delivered to a disease site in a coordinated fashion, thereby assuring that said ratio is maintained at the disease site.